Bezafibrate 100 MG ( DrugBank: Bezafibrate )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 93 | 原発性胆汁性胆管炎 | 1 |
93. 原発性胆汁性胆管炎
臨床試験数 : 282 / 薬物数 : 245 - (DrugBank : 56) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05239468 (ClinicalTrials.gov) | February 2022 | 28/1/2022 | Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Patients With PBC | A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis | Primary Biliary Cholangitis | Drug: Bezafibrate 100 MG;Drug: Bezafibrate 200 MG;Drug: Obeticholic Acid 5 MG;Drug: Obeticholic Acid placebo;Drug: Bezafibrate Placebo | Intercept Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States |